Dynavax Technologies
Commercial-stage biopharmaceutical company focused on development, manufacturing and commercialization of vaccines. Scientific focus centers on adjuvant technologies that target innate immune receptors (notably TLR biology) to enhance vaccine immunogenicity. Activities include clinical development, out-licensing and partnerships, biomanufacturing, regulatory submissions and publication of preclinical and clinical findings.
Industries
Nr. of Employees
large (251-1000)
Dynavax Technologies
Patents
Immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US-12296002-B2
View DetailsAlkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof
US-11981670-B2
View Details
Immunogenic composition against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US-12296002-B2
View DetailsAlkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof
US-11981670-B2
View DetailsProducts
HEPLISAV-B
Recombinant hepatitis B vaccine formulated with a TLR9-targeting adjuvant for prevention of hepatitis B infection in adults 18 years and older. Approved and marketed in multiple jurisdictions.
Clinical-stage herpes zoster vaccine candidate (z-1018)
Phase 1/2 randomized, observer-blinded trial evaluating safety, tolerability and immunogenicity of an investigational herpes zoster vaccine candidate formulated with a TLR9-targeting adjuvant.
rF1V plague vaccine candidate (rF1V with adjuvant)
Phase 2 randomized trial evaluating immunogenicity and safety of a recombinant plague vaccine candidate formulated with a TLR-targeting adjuvant.
CpG 1018
Dynavax’s proprietary toll-like receptor 9 (TLR9) agonist adjuvant designed to increase antibody concentrations and stimulate strong immune responses.
Biovac-B
A 3-dose hepatitis B vaccine utilizing Hansenula polymorpha technology, out-licensed to Wockhardt Ltd, India.
Gen Vax B
A 3-dose hepatitis B vaccine utilizing Hansenula polymorpha technology, out-licensed to Serum Institute of India.
HEPLISAV-B
Recombinant hepatitis B vaccine formulated with a TLR9-targeting adjuvant for prevention of hepatitis B infection in adults 18 years and older. Approved and marketed in multiple jurisdictions.
Clinical-stage herpes zoster vaccine candidate (z-1018)
Phase 1/2 randomized, observer-blinded trial evaluating safety, tolerability and immunogenicity of an investigational herpes zoster vaccine candidate formulated with a TLR9-targeting adjuvant.
rF1V plague vaccine candidate (rF1V with adjuvant)
Phase 2 randomized trial evaluating immunogenicity and safety of a recombinant plague vaccine candidate formulated with a TLR-targeting adjuvant.
CpG 1018
Dynavax’s proprietary toll-like receptor 9 (TLR9) agonist adjuvant designed to increase antibody concentrations and stimulate strong immune responses.
Biovac-B
A 3-dose hepatitis B vaccine utilizing Hansenula polymorpha technology, out-licensed to Wockhardt Ltd, India.
Gen Vax B
A 3-dose hepatitis B vaccine utilizing Hansenula polymorpha technology, out-licensed to Serum Institute of India.
Services
Providing TLR-targeting oligonucleotide adjuvant technology to selected research institutions and partners to support adjuvanted vaccine development.
Process development, GMP manufacturing support and technology transfer for recombinant antigens and vaccine candidates using established yeast expression platforms.
Providing TLR-targeting oligonucleotide adjuvant technology to selected research institutions and partners to support adjuvanted vaccine development.
Process development, GMP manufacturing support and technology transfer for recombinant antigens and vaccine candidates using established yeast expression platforms.
Expertise Areas
- Vaccine development
- Adjuvant development (TLR agonists)
- Clinical trial management
- Biomanufacturing and process development
Key Technologies
- Toll-like receptor (TLR) biology and TLR9-targeting synthetic oligonucleotide adjuvants
- TLR7/8 agonist development
- Yeast expression system (Hansenula polymorpha) for recombinant protein production
- Recombinant antigen production
News & Updates
Announcement regarding acquisition agreement to add a marketed adult hepatitis B vaccine and a Phase 1/2 shingles candidate to the acquirer's pipeline.
Notice of company participation at an industry healthcare conference.
Quarterly financial results release and announcement of a share repurchase program.
Curated list of peer-reviewed publications and conference presentations on TLR biology, adjuvant development and clinical trial results.
Announcement regarding acquisition agreement to add a marketed adult hepatitis B vaccine and a Phase 1/2 shingles candidate to the acquirer's pipeline.
Notice of company participation at an industry healthcare conference.
Quarterly financial results release and announcement of a share repurchase program.
Curated list of peer-reviewed publications and conference presentations on TLR biology, adjuvant development and clinical trial results.